Compare Raymond James Financial, Inc. (RJF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Viatris Inc — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| RJF | VTRS | |
|---|---|---|
Market Cap | $32.73B | $20.50B |
Sector | Financials | Health |
52-Week High | $176.43 | $17.59 |
52-Week Low | $140.89 | $8.74 |
Dividend Yield | 1.29% | 2.73% |
Enterprise Value | — | $32.71B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
